Cargando…
Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer
INTRODUCTION: Androgen deprivation therapy (ADT) is a mainstay of treatment against advanced prostate cancer (PC). As a treatment goal, suppression of plasma testosterone levels to <50 ng/dl has been established over decades. Evidence is growing though that suppression to even lower levels may ad...
Autores principales: | Breul, Jürgen, Lundström, Eija, Purcea, Daniela, Venetz, Werner P., Cabri, Patrick, Dutailly, Pascale, Goldfischer, Evan R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331090/ https://www.ncbi.nlm.nih.gov/pubmed/28028737 http://dx.doi.org/10.1007/s12325-016-0466-7 |
Ejemplares similares
-
Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study
por: Peltier, Alexandre, et al.
Publicado: (2015) -
Sustained In-Vivo Release of Triptorelin Acetate from a Biodegradable Silica Depot: Comparison to Pamorelin(®) LA
por: Forsback, Ari-Pekka, et al.
Publicado: (2021) -
Changes in Body Image in Patients with Prostate Cancer over 2 Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study
por: van den Driessche, Hans, et al.
Publicado: (2016) -
Preparation and In-vitro Evaluation of Controlled Release PLGA Microparticles Containing Triptoreline
por: Mahboubian, Alireza, et al.
Publicado: (2010) -
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
por: Merseburger, Axel S., et al.
Publicado: (2016)